Substance use in pregnancy: The medical challenge

Abstract

Substance use contributes significantly to the global burden of disease. Growing numbers of women use nicotine, alcohol, and illicit substances. Women are the most vulnerable to problematic substance use in their reproductive years. The first 1000 days of life, starting at conception, have been established as a critical window of time for long-term health and development. Substance use in pregnancy is associated with negative pregnancy and child health outcomes. The impact of antenatal substance use on these outcomes needs to be considered within a challenging and complex context. This review provides an overview of the current literature on the impact of substances on pregnancy and child outcomes as well as the evidence and guidelines on screening and interventions for women using substances during pregnancy.

Keywords

High-risk pregnancy drugs (abuse)complications maternal–fetal medicine

Introduction

Substance use disorders are a significant, preventable contributor to the global burden of disease.¹ According to the United Nations Office on Drugs and Crime 2017 report, cannabis remains the most common illicit drug used globally followed by amphetamines.² Opioids cause the highest negative health impact, and many people are poly drug users.² Biological, psychosocial, and cultural factors lead to sex and gender differences in the prevalence, patterns, and experiences of substance use.^3–6 While men currently have higher prevalence rates of substance use disorders, the gender gap is narrowing with growing numbers of women using nicotine, alcohol, and illicit substances.⁷ Once women start using substances, they increase their rate of use more rapidly and progress more quickly to substance use disorders than men.² Women are at greatest risk of developing a substance use disorder in their reproductive years with the highest prevalence rates seen in adolescence and early adulthood.⁸

According to a 2013 national survey in the United States of America (USA), the rate of cigarette use in pregnancy was 15.4%, alcohol use 9.4%, and illicit substance use 5.4%.⁹ In Australia, alcohol is the most commonly used drug in pregnancy.¹⁰ Findings from a population-based cohort revealed that 27% of Australian women drank in the first trimester, and 27% continued to drink alcohol at some level during pregnancy.¹¹ In other studies, 13.8% of Australian women reported cigarette smoking in the first 20 weeks of pregnancy,¹² and 5% of women screened were using cannabis and 2% other illicit drugs in pregnancy.¹³ There is limited information on the prevalence of substance use in pregnancy in low- and middle-income countries. In a South African survey among pregnant women, 19.6% of women tested positive for alcohol and 8.8% positive for at least one drug (methamphetamine, cannabis, Mandrax).¹⁴ While a study using self-report measures found that 36.8% of women smoked cigarettes, 20.2% used alcohol and 4% used illicit substances at the time of their first antenatal visit.¹⁵ High rates of polysubstance use have been shown in pregnant women using substances.^16–18 The rates of comorbid cigarette smoking are particularly high in pregnant women using substances, and poly substance users have even higher odds of smoking.¹⁹

The first 1000 days of life, starting at conception, have been established as a critical window of time for long-term health and development.^20,21 It is therefore crucial to understand the impact substance use has on pregnancy, breastfeeding, maternal–infant bonding, and child outcomes. This review provides an overview of the current literature on the impact of substances on pregnancy and child outcomes as well as the evidence and guidelines on screening and interventions for women using substances during pregnancy. This is a broad review of most substances used in pregnancy and is aimed at the general obstetrician and obstetric medicine specialist.

The impact of substances on pregnancy and child outcomes

Risk factors for problematic substance use in pregnancy include past alcohol, nicotine or illicit drug use, unintended pregnancy, lower level of education, unemployment, younger age, comorbid physical and mental health problems, childhood trauma, environmental stress, intimate partner violence, easy access to substances, and lack of knowledge of the impact of substances on fetal development.^22–25

Globally, 41% of all pregnancies are unintended which means that many women use substances before they become aware of their pregnancy.²⁶ Substance use itself increases the risk of unintended pregnancy.²⁷ For many women, pregnancy is a motivation to stop using substances, to cut back on their use, or to engage with harm reduction services such as opioid substitution programmes.²⁸ However, the chronic and relapsing nature of substance use disorders means that some women are unable to stop using in pregnancy. For those who manage to achieve abstinence during pregnancy, the rates of relapse in the first six months postpartum are high.²⁹ In a prospective USA study, 83% of women (N=152) achieved abstinence to at least one substance in pregnancy, but in the postpartum period, 80% relapsed to at least one substance.²⁹

Pregnant women with substance use disorders are less likely to receive antenatal care than pregnant women not using substances.^30,31 Barriers to accessing antenatal care include the impact of underlying medical and psychiatric comorbidities, poor coping skills, transport and child care difficulties, intimate partner violence, incarceration, poor provider communication, stigmatization, fear of being reported to the police, losing child custody or other legal consequences, and negative health belief factors such as having an external locus of control, lack of belief in the efficacy of health care, and lack of trust in health care providers.^32–34 In addition to poor antenatal care, substance using women also carry burdens of psychiatric and medical comorbidities and negative psychosocial environments.^35,36 This context makes it challenging to determine the impact an individual drug has on pregnancy and child outcomes. Factors that influence pregnancy and child outcomes in substance using mothers include the dose, duration, and pattern of substance use, exposure to multiple substances, inadequate prenatal care, poor nutrition, medical comorbidities, psychiatric comorbidities, intimate partner violence, poor maternal–infant bonding, and chaotic postnatal environments.^37–51

In spite of the complexity of the context within which peripartum substance use takes place, it is known that substances of abuse have negative effects on maternal physiology and readily cross the placenta impacting on fetal development and brain growth.⁵² An overview of the effects of alcohol, nicotine, cannabis, opioids, cocaine, and methamphetamine on pregnancy and child outcomes is provided below.

Alcohol

Alcohol is a well-established teratogen, and fetal alcohol spectrum disorders (FASD) are globally the leading known form of preventable birth defects and developmental disabilities.⁵³ Findings from a recent meta-analysis report that eight out of 1000 in the general population have FASD and that one of every 13 pregnant women who consumed alcohol during pregnancy delivered a child with FASD.⁵⁴ The amount, timing, and pattern of drinking may impact FASD outcomes.⁵⁵ Alcohol use in pregnancy is associated with other long-term negative child outcomes including growth deficits,⁵⁶ behavior problems,^57,58 and cognitive and motor deficits.^52,59 Heavy alcohol use is associated with negative pregnancy outcomes such as miscarriage,⁶⁰ stillbirth,⁶¹ low birth weight,⁶² small-for-gestational age,⁶² preterm delivery,⁶³ and infant mortality.⁶⁴ Findings regarding pregnancy outcomes for low or very low alcohol intake are mixed.^65,66

Women receive conflicting messages regarding how much alcohol is safe during pregnancy.⁶⁷ Animal models demonstrate that all stages of embryonic development are vulnerable to the teratogenic effects of alcohol⁶⁸ and that even low levels of alcohol exposure impact brain development.⁶⁹ Given the well-established risk of teratogenicity and the potential negative long-term child outcomes even at low levels of consumption,^57,70 no amount of alcohol use in pregnancy can be considered safe. Most guidelines recommend abstinence in pregnancy, and health practitioners should give a consistent message regarding abstinence.^71–74

Nicotine

Nicotine is the primary psychoactive component of tobacco, and it passes readily through the placenta.⁷⁵ Cigarettes contain many harmful products, and animal studies have shown that nicotine itself is toxic for the developing brain.⁵² In rodent studies, prenatal and early postnatal nicotine exposure interfered with catecholamine and brainstem autonomic nuclei development and altered development of the neocortex, hippocampus, and cerebellum.⁷⁶ Animal models also show defective metabolic, reproductive, respiratory, and cardiovascular outcomes in nicotine-exposed offspring, suggesting that nicotine alone may be responsible for many of the negative long-term health outcomes in exposed offspring.⁷⁷ Prenatal nicotine exposure in humans is associated with increased risk of orofacial clefting and potentially a range of other congenital anomalies.⁷⁸ Cigarette smoking also negatively impacts child health outcomes. Neonates are at increased risk of infections,⁷⁹ cochlear dysfunction,⁸⁰ sudden infant death syndrome,⁸¹ and infant mortality.^82,83 Longer-term negative child outcomes include poorer cognitive development,⁸⁴ behavior problems,^85,86 childhood obesity,⁸⁷ hypertension, diabetes, and respiratory complications.⁸⁸ In a recent review, Holbrook⁷⁸ concludes that prenatal nicotine exposure has multiple, irreversible, negative impacts on child health, scholastic achievement, and behavior. Cigarette smoking is associated with multiple negative pregnancy outcomes including miscarriage,⁸⁹ ectopic pregnancy,^90,91 preterm premature rupture of membranes,⁹² abruptio placentae,⁹³ placenta praevia,⁹⁴ intrauterine growth restriction,⁹⁵ small-for-gestational age,^96,97 preterm delivery,⁹⁸ low birth weight,^95,96,98 stillbirth, and perinatal death.^98,99 The amount and timing of smoking may impact on these negative outcomes with greater amounts and continuous smoking throughout pregnancy having worse outcomes.^97–99 Stopping smoking in pregnancy is associated with improved pregnancy and child health outcomes including reductions in the incidence of low birth weight, preterm birth, and intensive care unit (ICU) admissions.¹⁰⁰ Interestingly, cigarette smoking in pregnancy reduces the risk of preeclampsia, but the other negative consequences clearly outweigh the benefit of any potential risk reduction.¹⁰¹

Some women view electronic nicotine delivery systems (ENDS) as safer than cigarettes and therefore potential harm reduction tools in pregnancy.^102,103 However, the research on the safety and efficacy of ENDS in pregnancy is lacking.^104,105 The World Health Organization (WHO) cautions pregnant women against the use of ENDS because of the potential long-term consequences for fetal brain development.¹⁰⁶ Many women also report using ENDS as an aid to smoking cessation during pregnancy.¹⁰⁷ Yet, a recent systematic review and meta-analysis of ENDS in nonpregnant patients concluded that there is very limited evidence on the impact of ENDS on smoking reduction or cessation.¹⁰⁸

Cannabis

Cannabis is lipophilic; it readily crosses the placental barrier¹⁰⁹ and impacts on fetal brain development.¹¹⁰ Many women perceive cannabis to be safe in pregnancy.¹¹¹ However, cannabis has teratogenic potential, and its use is associated with anencephaly¹¹² and adverse effects on neurodevelopment.¹¹³ Negative child outcomes include smaller head circumferences,¹¹⁴ learning and cognitive problems (particularly executive function deficits),^115–119 depression,¹²⁰ aggression, and behavior problems.^115,121 Negative pregnancy outcomes associated with cannabis use include low birth weight,^122–124 small-for-gestational age,¹²³ preterm delivery,^124,125 stillbirth,¹²⁶ and placement in neonatal ICUs.^122,124

There is growing use of medical cannabis for a range of health conditions including pregnancy-associated hyperemesis.¹²⁷ However, the safety of medical cannabis in pregnancy has not yet been established.¹¹³ The American College of Obstetricians and Gynecologists (ACOG) advises that pregnant women and women planning pregnancy should discontinue medical cannabis and rather use agents with better pregnancy-specific safety data.¹²⁸

Opioids

Opioids used in pregnancy include heroin and prescription opioids. USA studies have shown an increase in antenatal maternal opioid use in the last decade with a fivefold corresponding increase in neonatal abstinence syndrome (NAS).^129,130 Currently, no strong teratogenic effect has been demonstrated for opioids, while there is uncertainty about a possible weak effect for synthetic opioids on cardiovascular defects.¹³¹ Additional negative child health outcomes associated with opioid exposure include sudden infant death syndrome,^132,133 postnatal growth deficiency, and cognitive and neurobehavioral problems.^52,134 Maternal opioid use is associated with increased risk of maternal death during hospitalization.¹³⁵ Negative pregnancy outcomes include intrauterine growth restriction,^135,136 oligohydraminos,¹³⁵ low birth weight,¹³⁷ preeclampsia,¹³¹ placental insufficiency and abruption,¹³⁵ premature rupture of membranes,¹³⁵ preterm labour,^135,136 postpartum hemorrhage,¹³⁸ and stillbirth.^135,136

Neonates are at risk of NAS with exposure to illicit and prescription opioids.^139,140 Longer and late exposure to prescription opioids increases the risk of NAS.¹³⁹ NAS presents clinically with tremors, irritability, excessive crying, diarrhea, and seizures.¹⁴⁰ Rates of nicotine use are high in opioid-using women, and cigarette smoking is associated with greater negative pregnancy outcomes¹⁴¹ and delay and worsening of NAS.¹⁴²

Cocaine

Cocaine causes a catecholamine surge, and use in pregnancy has been associated with significant maternal morbidity including hypertensive crisis, myocardial infarction, cerebrovascular events, pulmonary edema, aortic dissection, and renal failure.^143,144 Human and animal studies show teratogenic potential including cardiac, central nervous system, genitourinary, gastrointestinal, and limb malformations.^145–150 Other long-term negative child health outcomes include growth restriction,¹⁵¹ neurodevelopmental and behavior problems, and cognitive deficits in language and executive function.^152,153 The negative pregnancy outcomes associated with cocaine use include preterm premature rupture of membranes,¹⁵⁴ preeclampsia, placental abruption and infarction,¹⁵⁵ preterm birth,¹⁵⁶ low birth weight,¹⁵⁶ small-for-gestational age,¹⁵⁶ and intrauterine death.¹⁵⁷

Methamphetamine

Methamphetamine exposure has not been shown to be directly teratogenic.⁵² Exposed infants are however more likely to be growth restricted,⁵² to have difficulty feeding, and to require ICU admission.¹⁵⁸ There is also an increased risk of neonatal and infant death.^159,160 There is limited data on the longer-term child outcomes of methamphetamine exposure in pregnancy. Children may be at risk for developmental and behavioral effects^161,162 and cognitive problems.^163–165 Negative pregnancy outcomes associated with methamphetamine use include low birth weight,¹⁶⁶ shorter gestational age,¹⁶⁶ preterm birth,^159,167 preeclampsia,¹⁵⁹ gestational hypertension,¹⁵⁹ placental abruption,¹⁵⁹ and intrauterine death.^159,168

Screening for substance use in pregnancy

Expert panels and organization guidelines recommend universal screening for substance use in pregnancy.^72,169–172 There are several barriers to routine screening including resource limitations and health care provider attitudes.^173–175 Health providers often hold stigmatizing views of women who use substances in pregnancy.¹⁷⁶ The US Centers for Disease Control and Prevention Expert Meeting on Perinatal Illicit Drug Use concluded that screening for substance use in pregnancy should be done at the first antenatal visit and repeated at least every trimester for women who screened positive.¹⁶⁹ They also recommend annual screening for nicotine, alcohol, and illicit drug use as part of routine well-woman care.¹⁶⁹ The WHO Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy recommend asking about substance use as early as possible in pregnancy and at every antenatal visit.⁷²

Screening instruments that have been used in pregnancy include the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST),¹⁷⁷ Take–number of drinks, Annoyed, Cut-down, Eye-Opener (T-ACE),¹⁷⁸ Tolerance, Worried, Eye-Opener, Amnesia, Kut down (TWEAK),¹⁷⁹ Substance Use Risk Profile-Pregnancy (SURP-P),¹⁸⁰ Past, Present, Parents, Partner (4P’s Plus),¹⁸¹ Cut-down, Annoyed, Guilt, Eye-Opener (CAGE),¹⁸² Short Michigan Alcohol Screening Test (SMAST),¹⁸³ Normal drinker, Eye-Opener, Tolerance (NET),¹⁸⁴ Alcohol Use Disorder Identification Test (AUDIT),¹⁸⁵ and Alcohol Use Disorder Identification Test-Consumption (AUDIT-C).¹⁸⁶ In a 2010 systematic review of brief screening questionnaires used to identify problem drinking in pregnancy, the T-ACE, TWEAK, and AUDIT-C had high sensitivity and specificity, while the CAGE and SMAST performed poorly.¹⁸⁷

Screening can also be done by asking standard questions during an interview. Open-ended questions may be more likely to lead to disclosure of substance use.^169,171 Either way, screening for substance use in pregnancy needs to be done in a nonjudgmental manner. Women may only feel comfortable disclosing once they have established rapport with their clinician. A positive screen does not imply a diagnosis but does encourage further discussion around health behaviors and consideration of further management.¹⁸⁸

Drug testing should only be done with the consent of the woman and if it is clinically indicated as part of an overall management plan.¹⁶⁹ Urine drug screening is the method of choice when testing for substance use is indicated.¹⁷¹

Interventions

Pregnant women are more likely to need treatment for substance use compared to nonpregnant women, but they are less likely to receive any.¹⁸⁹ Interventions for substance using pregnant women should be individualized based on the woman, her context, and the available resources.⁷² The Screening, Brief Intervention and Referral to Treatment (SBIRT) model is a cost-effective primary care model that has been recommended in pregnancy.^169,190 When screening reveals substance use, pregnant women should be offered brief interventions and referred for more focused interventions as needed.^72,169 All women should be given information on the risks associated with substance use in pregnancy.

For women needing referral for treatment of substance use in pregnancy, the ideal is to offer collaborative care with addiction, mental health, and social services. Programmes with combined prenatal care and substance use or mental health treatments have shown improved outcomes such as decreased prenatal substance use and decreased need for assisted ventilation at birth.^191–193 If possible, services should be offered at a single location with coordinated care. Where appropriate, the woman’s partner should be involved in treatment and referred for intervention if needed.

Psychosocial interventions

There are only a few effective therapies for the treatment of substance use during pregnancy.¹⁹⁴ Brief interventions include psychoeducation, counseling, and motivational interviewing techniques.¹⁹⁰ A 2015 Cochrane review of psychosocial interventions for pregnant women in outpatient illicit drug programmes included nine studies of contingency management and five studies of motivational interviewing-based interventions.¹⁹⁵ The authors conclude that current evidence does not show improved outcomes and that better evidence is needed to evaluate psychosocial interventions.¹⁹⁵ In contrast, a 2017 review of psychosocial interventions for smoking in pregnancy found high-quality evidence for the effectiveness of counseling, incentive-based interventions, and feedback.¹⁰⁰ Women who received psychosocial interventions had a 17% reduction in low birth weight infants and 22% reduction in neonatal ICU admissions.¹⁰⁰ Reviews on psychosocial interventions for alcohol use have concluded that there are limitations in the amount and quality of available evidence and little evidence to support intervention effectiveness.^196–198 In South Africa, the country with the highest global prevalence rates of FASD,⁵⁴ motivational interviewing,¹⁹⁹ community-based educational interventions,²⁰⁰ and case management interventions²⁰¹ have been successful in reducing drinking in pregnancy and rates of FASD.

Pharmacological interventions

Alcohol

The safety and efficacy of medications used for alcohol dependence have not been established in pregnancy.^202,203 Detoxification may be indicated for women using heavy amounts of alcohol. The timing of detoxification should be based on risk assessment of continued alcohol exposure to the fetus.²⁰⁴ Rapid alcohol withdrawal may lead to fetal distress and death so is best done as an in-patient with close obstetric and medical supervision.²⁰² The data on the use of benzodiazepines for alcohol withdrawal in pregnancy are limited and conflicting.²⁰³ Disulfiram, an acetyl dehydrogenase inhibitor, causes a severe reaction when combined with alcohol, and its use may put pregnant women at risk.²⁰³ There are also conflicting reports on teratogenicity following first trimester exposure.^205,206 Its use in pregnancy is not currently recommended.²⁰⁷ The nonselective opioid receptor antagonist naltrexone has been shown to reduce the rates of heavy drinking in the nonpregnant population, but there are currently no published studies for the treatment of alcohol use disorders in pregnant women.²⁰³ Studies in opioid-using mothers have not found negative effects on birth outcomes or increased rates of fetal anomalies, but data are lacking, and further studies are needed.^208–210 Acamprosate modulates glutamatergic neurotransmission, and it is effective in maintaining abstinence following detoxification in the nonpregnant population.²¹¹ There are currently no studies in pregnant women.

Nicotine

The safety and efficacy of pharmacological interventions for nicotine smoking have not yet been established.²¹² A 2015 Cochrane review of nicotine replacement products found no evidence that nicotine replacement therapy (NRT) had positive or negative impact on birth outcomes but that they may promote health development outcomes in infants.¹⁰⁴ A review by Bruin et al.⁷⁷ concludes that although human data on the long-term effects of NRT are lacking, there is sufficient evidence from animal models to suggest that many negative long-term developmental effects can be attributed to nicotine alone. A recent ACOG committee opinion advises that NRT be closely supervised and only initiated after a discussion about the known risks of continued smoking versus nicotine replacement.²¹³ NRT should be only be used with a clear decision to stop smoking.²¹³ Intermittent products such as gums should be used at the lowest doses.²⁰² There are ongoing studies assessing the partial nicotinic acetylcholine receptor agonist varenicline and the antidepressant bupropion for smoking cessation in pregnancy. Small studies of varenicline’s safety in pregnancy have not found teratogenicity, but data are lacking.^104,214 Likewise, there is limited data on bupropion, but it has no known risk of fetal anomalies.^215–218 In a recent small randomized placebo-controlled trial, bupropion increased smoking cessation rates and decreased craving, but there were no differences in abstinence rates at the end of pregnancy.²¹⁹

Opioids

Medication-assisted withdrawal from opioids reduces fetal exposure to opioids but is not recommended because of high rates of opioid relapse rates and increased adverse outcomes.²²⁰ Pregnant women using opioids are best managed with opioid maintenance treatment.^221,222 ACOG discourages the use of medically assisted withdrawal if maintenance treatments are available.²²³ Both methadone and buprenorphine treatment have been shown to significantly improve maternal, fetal, and neonatal outcomes.²²¹ A randomized control trial comparing methadone and buprenorphine showed that infants exposed to buprenorphine had shorter treatment for NAS, required lower doses of morphine, and had shorter hospital stays.²²⁴ However, methadone is superior in retaining women in treatment.²²⁵ Compared to methadone, buprenorphine has lower retention rates with flexibly delivered and low fixed doses but is equally effective when fixed medium or high doses are used.²²⁵ Both methadone and buprenorphine cross the placental barrier and have been shown to impact pregnancy outcomes, fetal neurodevelopmental behavior, and long-term child outcomes.^52,226,227 A 2013 Cochrane review concluded that there is currently insufficient data to recommend one treatment over the other.²²⁸ Naltrexone is used as a treatment for relapse prevention, but use in pregnancy is not currently advised as detoxification is required and more research is needed in pregnant women.²²⁹

Cannabis and stimulants

For cannabis and stimulants, medications are not routinely required for withdrawal. There are currently no recommended pharmacological interventions for cannabis and stimulant use in pregnancy.¹⁹⁴

Conclusions

Substance use is prevalent in women of reproductive age. Substance use disorders need to be conceptualized as chronic, relapsing conditions that will have an impact on women and families during pregnancy and the postpartum period. All pregnant women and women planning pregnancy should be screened for problematic substance use. Women also need to be screened for psychiatric and medical comorbidities.

Pregnancy is an important opportunity to engage with substance using women. Early antenatal care should be encouraged and the method and frequency of antenatal monitoring determined by the presence of complications such as intrauterine growth restriction. Tailored, safe, and acceptable substance use treatments should be implemented early on. Brief interventions should be offered first followed by more intensive, targeted treatments as needed. Where resources allow, collaborative care with mental health or addiction services should be offered. Given the high rates of relapse, long-term care is required with assertive outreach and relapse prevention strategies. More research is needed on pharmacological treatment options for substance using pregnant women.

Footnotes

Acknowledgements

None

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Guarantor

Dr Kerry-Ann Louw will act as the guaranteeing author for this paper.

Contributorship

Sole author

References

Degenhardt

Whiteford

Ferrari

et al . Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564–1574.

UNODC. Global overview of drug demand and supply, https://www.unodc.org/wdr2017/field/Booklet_2_HEALTH.pdf (2017, accessed 13 December 2017).

Zilberman

Tavares

el-Guebaly

Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. J Addict Dis 2003; 22: 61–74.

Lynch

Roth

Carroll

ME.

Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 2002; 164: 121–137.

Wagner

Anthony

JC.

Male-female differences in the risk of progression from first use to dependence upon cannabis, cocaine, and alcohol. Drug Alcohol Depend 2007; 86: 191–198.

Kloos

Weller

Chan

et al . Gender differences in adolescent substance abuse. Curr Psychiatry Rep 2009; 11: 120–126.

McHugh

Wigderson

Greenfield

SF.

Epidemiology of substance use in reproductive-age women. Obstet Gynecol Clin North Am 2014; 41: 177–189.

Merikangas

McClair

VL.

Epidemiology of substance use disorders. Hum Genet 2012; 131: 779–789.

Lipari

Hedden

Hughes

Substance use and mental health estimates from the 2013 National Survey on Drug Use and Health: overview of findings. Rockville (MD): Substance Abuse and Mental Health Services Administration (US), 2013.

10.

Cameron

Davey

Kendall

et al . Changes in alcohol consumption in pregnant Australian women between 2007 and 2011. Med J Aust 2013; 199: 355–357.

11.

Muggli

O’leary

Donath

et al . Did you ever drink more? A detailed description of pregnant women’s drinking patterns. BMC Public Health 2016; 16: 683.

12.

Zeki

Hilder

et al . Australia’s mothers and babies 2010, Perinatal statistics series no. 27. Cat. no. PER 57. Canberra: AIHW), https://www.aihw.gov.au/getmedia/a5e20cf4-e032-4452-bf07-eb51bb124470/14513.pdf.aspx?inline=true (2012, accessed 13 December 2017).

13.

Wallace

Burns

Gilmour

Substance use, psychological distress and violence among pregnant and breastfeeding Australian women. Aust N J Z Public Health 2007; 31: 51–56.

14.

Petersen W

Jordaan

Mathews

et al . Alcohol and other drug use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa. Adv Prev Med 2014; 1: 1–10.

15.

Vythilingum

Roos

Faure

et al . Risk factors for substance use in pregnant women in South Africa. S Afr Med J 2012; 102: 853–854.

16.

Reitan

Patterns of polydrug use among pregnant substance abusers. Nord Stud Alcohol Drugs 2017; 34: 145–159.

17.

Delano

Gareri

Koren

Rates of fetal polydrug exposures in methadone-maintained pregnancies from a high-risk population. PLoS One 2013; 8: e82647.

18.

Terplan

Smith

Glavin

SH.

Trends in injection drug use among pregnant women admitted into drug treatment: 1994–2006. J Womens Health (Larchmt) 2010; 19: 499–505.

19.

Fallin

Miller

Ashford

Smoking among pregnant women in outpatient treatment for opioid dependence: a qualitative inquiry. Nicotine Tob Res 2016; 18: 1727–1732.

20.

Black

Walker

Fernald

; for the Lancet Early Childhood Development Series Steering Committee. Early childhood development coming of age: science through the life course. Lancet 2017; 389: 77–90.

21.

Britto

Lye

Proulx

et al . Nurturing care: promoting early childhood development. Lancet 2017; 389: 91–102.

22.

Trussell

The cost of unintended pregnancy in the United States. Contraception 2007; 75: 168–170.

23.

Wendell

AD.

Overview and epidemiology of substance abuse in pregnancy. Clin Obstet Gynecol 2013; 56: 91–96.

24.

Bailey

Hill

Hawkins

et al . Men’s and women’s patterns of substance use around pregnancy. Birth 2008; 35: 50–59.

25.

Powers

McDermott

Loxton

et al . A prospective study of prevalence and predictors of concurrent alcohol and tobacco use during pregnancy. Matern Child Health J 2013; 17: 76–84.

26.

Singh

Sedgh

Hussain

Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann 2010; 41: 241–250.

27.

Heil

Jones

Arria

et al . Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 2011; 40: 199–202.

28.

Higgins

Clough

Frank

et al . Changes in health behaviors made by pregnant substance users. Int J Addict 2009; 30: 1323–1333.

29.

Forray

Merry

Lin

et al . Perinatal substance use: a prospective evaluation of abstinence and relapse. Drug Alcohol Depend 2015; 150: 147–155.

30.

Friedman

Heneghan

Rosenthal

Characteristics of women who do not seek prenatal care and implications for prevention. J Obstet Gynecol Neonatal Nurs 2009; 38: 174–181.

31.

Lagasse

Wouldes

et al . Predictors of inadequate prenatal care in methamphetamine-using mothers in New Zealand and the United States. Matern Child Health J 2013; 17: 566–575.

32.

Goodman

Improving access to maternity care for women with opioid use disorders: colocation of midwifery services at an addiction treatment program. J Midwifery Womens Health 2015; 60: 706–712.

33.

Schempf

Strobino

DM.

Drug use and limited prenatal care: an examination of responsible barriers. Am J Obstet Gynecol 2009; 200: 412.e1–412.e10.

34.

Gopman

Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin North Am 2014; 41: 213–228.

35.

Gyarmathy

Giraudon

Hedrich

et al . Drug use and pregnancy – challenges for public health. Euro Surveill 2009; 14: 33–36.

36.

Ehrmin

JT.

Unresolved feelings of guilt and shame in the maternal role with substance-dependent African American women. J Nurs Scholarsh 2001; 33: 47–52.

37.

Tuten

Heil

O'grady

et al . The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse 2009; 35: 358–363.

38.

Benningfield

Arria

Kaltenbach

et al . Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict 2010; 19: 416–421.

39.

Havens

Simmons

Shannon

et al . Factors associated with substance use during pregnancy: results from a national sample. Drug Alcohol Depend 2009; 99: 89–95.

40.

Hutchins

DiPietro

Psychosocial risk factors associated with cocaine use during pregnancy: a case-control study. Obstet Gynecol 1997; 90: 142–147.

41.

Mansoor

Morrow

Accornero

et al . Longitudinal effects of prenatal cocaine use on mother-child interactions at ages 3 and 5 years. J Dev Behav Pediatr 2012; 33: 32–41.

42.

Strathearn

Mayes

LC.

Cocaine addiction in mothers: potential effects on maternal care and infant development. Ann N Y Acad Sci 2010; 1187: 172–183.

43.

Wouldes

Woodward

LJ.

Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol 2010; 32: 406–413.

44.

Sarfi

Sundet

Waal

Maternal stress and behavioral adaptation in methadone- or buprenorphine-exposed toddlers. Infant Behav Dev 2013; 36: 707–716.

45.

Tronick

Messinger

Weinberg

et al . Cocaine exposure is associated with subtle compromises of infants’ and mothers’ social-emotional behavior and dyadic features of their interaction in the face-to-face still-face paradigm. Dev Psychol 2005; 41: 711–722.

46.

LaGasse

Seifer

Lester

BM.

Interpreting research on prenatal substance exposure in the context of multiple confounding factors. Clin Perinatol 1999; 26: 39–54, vi.

47.

Cleary

Eogan

O'connell

et al . Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012; 107: 1482–1492.

48.

Schempf

Strobino

DM.

Illicit drug use and adverse birth outcomes: is it drugs or context?

J Urban Health 2008; 85: 858–873.

49.

Strengell

Väisänen

Joukamaa

et al . Psychiatric comorbidity among substance misusing mothers. Nord J Psychiatry 2015; 69: 315–321.

50.

Winklbaur

Kopf

Ebner

et al . Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008a; 103: 1429–1440.

51.

Holbrook

Rayburn

WF.

Teratogenic risks from exposure to illicit drugs. Obstet Gynecol Clin North Am 2014; 41: 229–239.

52.

Ross

Graham

Money

et al . Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology 2015; 40: 61–87.

53.

Hoyme

Kalberg

Elliott

et al . Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders. Am Acad Pediatr 2016; 138: e20154256.

54.

Lange

Probst

Gmel

et al. Global prevalence of fetal alcohol spectrum disorder among children and youth: a systematic review and meta-analysis. JAMA Pediatrics. Epub ahead of print 21 August 2017. DOI: 10.1001/jamapediatrics.2017.1919.

55.

May

Blankenship

Marais

A-S

et al . Maternal alcohol consumption producing fetal alcohol spectrum disorders (FASD): quantity, frequency, and timing of drinking. Drug Alcohol Depend 2013; 133: 502–512.

56.

Jacobson

SW.

Drinking moderately and pregnancy. Effects on child development. Alcohol Res Health 1999; 23: 25–30.

57.

Sood

Delaney-Black

Covington

et al . Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. dose-response effect. Pediatrics 2001; 108: E34.

58.

Niclasen

Andersen

A-MN

Strandberg-Larsen

et al . Is alcohol binge drinking in early and late pregnancy associated with behavioural and emotional development at age 7 years? Eur Child Adolesc Psychiatry 2014; 23: 1175–1180.

59.

Kaplan-Estrin

Jacobson

JL.

Neurobehavioral effects of prenatal alcohol exposure at 26 months. Neurotoxicol Teratol 1999; 21: 503–511.

60.

Avalos

Roberts

SCM

Kaskutas

et al . Volume and type of alcohol during early pregnancy and the risk of miscarriage. Subst Use Misuse 2014; 49: 1437–1445.

61.

O'Leary

Jacoby

D'antoine

et al . Heavy prenatal alcohol exposure and increased risk of stillbirth. BJOG 2012; 119: 945–952.

62.

Patra

Bakker

Irving

et al . Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA) – a systematic review and meta-analyses. BJOG 2011; 118: 1411–1421.

63.

Srikartika

O'leary

CM.

Pregnancy outcomes of mothers with an alcohol-related diagnosis: a population-based cohort study for the period 1983-2007. BJOG 2015; 122: 795–804.

64.

Strandberg-Larsen

Grønboek

Andersen

A-MN

et al . Alcohol drinking pattern during pregnancy and risk of infant mortality. Epidemiology 2009; 20: 884–891.

65.

Henderson

Gray

Brocklehurst

Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG 2007; 114: 243–252.

66.

Han

J-Y

Choi

J-S

Ahn

H-K

et al . Foetal and neonatal outcomes in women reporting ingestion of low or very low alcohol intake during pregnancy. J Matern Fetal Neonatal Med 2012; 25: 2186–2189.

67.

Anderson

Hure

Kay-Lambkin

et al . Women’s perceptions of information about alcohol use during pregnancy: a qualitative study. BMC Public Health 2016; 14: 1048.

68.

Sulik

KK.

Fetal alcohol spectrum disorder: pathogenesis and mechanisms. Handb Clin Neurol 2014; 125: 463–475.

69.

Hamilton

Barto

Rodriguez

et al . Effects of moderate prenatal ethanol exposure and age on social behavior, spatial response perseveration errors and motor behavior. Behav Brain Res 2014; 269: 44–54.

70.

Glass

Ware

Mattson

SN.

Neurobehavioral, neurologic, and neuroimaging characteristics of fetal alcohol spectrum disorders. Handb Clin Neurol 2014; 125: 435–462.

71.

Carson

Cox

Crane

et al . Alcohol use and pregnancy consensus clinical guidelines. J Obstet Gynaecol Can 2010; 32: S1–S31.

72.

World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva, Switzerland: World Health Organization, 2014.

73.

American College of Obstetricians and Gynecologists and Committee on Health Care for Underserved Women. Committee Opinion No. 496: at-risk drinking and alcohol dependence: obstetric and gynecologic implications. Obstet Gynecol 2011; 118: 383–388.

74.

Group HEE and Officers UCM. Alcohol guidelines review – report from the guidelines development group to the UK Chief Medical Officers, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/545739/GDG_report-Jan2016.pdf (accessed 13 December 2017).

75.

Lambers

Clark

KE.

The maternal and fetal physiologic effects of nicotine. Semin Perinatol 1996; 20: 115–126.

76.

Dwyer

McQuown

Leslie

FM.

The dynamic effects of nicotine on the developing brain. Pharmacol Ther 2009; 122: 125–139.

77.

Bruin

Gerstein

Holloway

AC.

Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicol Sci 2010; 116: 364–374.

78.

Holbrook

BD.

The effects of nicotine on human fetal development. Birth Defects Res C Embryo Today 2016; 108: 181–192.

79.

Metzger

Halperin

Manhart

et al . Association of maternal smoking during pregnancy with infant hospitalization and mortality due to infectious diseases. Pediatr Infect Dis J 2013; 32: e1–e7.

80.

Durante

Ibidi

Lotufo

JPB

et al . Maternal smoking during pregnancy: impact on otoacoustic emissions in neonates. Int J Pediatr Otorhinolaryngol 2011; 75: 1093–1098.

81.

Zhang

Wang

Maternal smoking and increased risk of sudden infant death syndrome: a meta-analysis. Leg Med (Tokyo) 2013; 15: 115–121.

82.

Singh

Eng

Yel

et al . Maternal use of cigarettes, pipes, and smokeless tobacco associated with higher infant mortality rates in Cambodia. Asia Pac J Public Health 2013; 25: 64S–74S.

83.

Akinyemi

Adedini

Wandera

et al . Independent and combined effects of maternal smoking and solid fuel on infant and child mortality in sub-Saharan Africa. Trop Med Int Health 2016; 21: 1572–1582.

84.

Anthopolos

Edwards

Miranda

ML.

Effects of maternal prenatal smoking and birth outcomes extending into the normal range on academic performance in fourth grade in North Carolina, USA. Paediatr Perinat Epidemiol 2013; 27: 564–574.

85.

Stene-Larsen

Borge

AIH

Vollrath

ME.

Maternal smoking in pregnancy and externalizing behavior in 18-month-old children: results from a population-based prospective study. J Am Acad Child Adolesc Psychiatry 2009; 48: 283–289.

86.

Carter

Paterson

Gao

et al . Maternal smoking during pregnancy and behaviour problems in a birth cohort of 2-year-old Pacific children in New Zealand. Early Hum Dev 2008; 84: 59–66.

87.

Timmermans

Mommers

Gubbels

et al . Maternal smoking during pregnancy and childhood overweight and fat distribution: the KOALA Birth Cohort Study. Pediatr Obes 2014; 9: e14–e25.

88.

Banderali

Martelli

Landi

et al . Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. J Transl Med 2015; 13: 327.

89.

Pineles

Park

Samet

JM.

Systematic review and meta-analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol 2014; 179: 807–823.

90.

Rana

Kazmi

Singh

et al . Ectopic pregnancy: a review. Arch Gynecol Obstet 2013; 288: 747–757.

91.

Horne

Brown

Nio-Kobayashi

et al . The association between smoking and ectopic pregnancy: why nicotine is BAD for your fallopian tube. PLoS One 2014; 9: e89400.

92.

England

Benjamin

Abenhaim

HA.

Increased risk of preterm premature rupture of membranes at early gestational ages among maternal cigarette smokers. Am J Perinatol 2013; 30: 821–826.

93.

Høgberg

Rasmussen

Irgens

LM.

The effect of smoking and hypertensive disorders on abruptio placentae in Norway 1999-2002. Acta Obstet Gynecol Scand 2007; 86: 304–309.

94.

Andres

RL.

The association of cigarette smoking with placenta previa and abruptio placentae. Semin Perinatol 1996; 20: 154–159.

95.

Murphy

Dunney

Mullally

et al . Population-based study of smoking behaviour throughout pregnancy and adverse perinatal outcomes. Int J Environ Res Public Health 2013; 10: 3855–3867.

96.

Meghea

Rus

Cherecheş

et al . Maternal smoking during pregnancy and birth outcomes in a sample of Romanian women. Cent Eur J Public Health 2014; 22: 153–158.

97.

Miyake

Tanaka

Arakawa

Active and passive maternal smoking during pregnancy and birth outcomes: the Kyushu Okinawa maternal and child health study. BMC Pregnancy Childb 2013; 13: 157.

98.

Mei-Dan

Walfisch

Weisz

et al . The unborn smoker: association between smoking during pregnancy and adverse perinatal outcomes. J Perinat Med 2015; 43: 553–558.

99.

Pineles

Hsu

Park

et al . Systematic review and meta-analyses of perinatal death and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol 2016; 184: 87–97.

100.

Chamberlain

O'mara-Eves

Porter

et al . Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev 2017; 2: CD001055.

101.

Spinillo

Capuzzo

Egbe

et al . Cigarette smoking in pregnancy and risk of pre-eclampsia. J Hum Hypertens 1994; 8: 771–775.

102.

Wagner

Camerota

Propper

Prevalence and perceptions of electronic cigarette use during pregnancy. Matern Child Health J 2017; 21: 1655–1661.

103.

Wigginton

Gartner

Rowlands

IJ.

Is it safe to vape? Analyzing online forums discussing E-cigarette use during pregnancy. Womens Health Issues 2017; 27: 93–99.

104.

Coleman

Chamberlain

Davey

MA.

Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. Epub ahead of print 22 December 2015. DOI: 10.1002/14651858.CD010078.pub2/full.

105.

Meernik

Goldstein

AO.

A critical review of smoking, cessation, relapse and emerging research in pregnancy and post-partum. Br Med Bull 2015; 114: 135–146.

106.

World Health Organization. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy, http://apps.who.int/iris/bitstream/10665/94555/1/9789241506 076_eng.pdf?ua=1 (accessed 13 December 2017).

107.

Oncken

Ricci

Kuo

C-L

et al . Correlates of electronic cigarettes use before and during pregnancy. Nicotine Tob Res 2017; 19: 585–590.

108.

Dib El

Suzumura

Akl

et al . Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis. BMJ Open 2017; 7: e012680.

109.

Clapp

Keve

Vial

et al . Ovine placental perfusion balance: effect of marijuana smoke. Am J Obstet Gynecol 1988; 159: 1430–1434.

110.

Psychoyos

Vinod

KY.

Marijuana, spice ‘herbal high’, and early neural development: implications for rescheduling and legalization. Drug Test Anal 2013; 5: 27–45.

111.

Farr

Tong

et al . Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol 2015; 213: 201.e1–201.e10.

112.

van Gelder

MMHJ

Reefhuis

Caton

et al . Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology 2009; 20: 60–66.

113.

Jaques

Kingsbury

Henshcke

et al . Cannabis, the pregnant woman and her child: weeding out the myths. J Perinatol 2014a; 34: 417–424.

114.

Fried

Watkinson

Gray

Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 1999; 21: 513–525.

115.

Marroun El

Hudziak

Tiemeier

et al . Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug Alcohol Depend 2011; 118: 470–474.

116.

Goldschmidt

Richardson

Willford

et al . Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry 2008; 47: 254–263.

117.

Fried

Watkinson

Gray

Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2003; 25: 427–436.

118.

Fried

Watkinson

Gray

Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1998; 20: 293–306.

119.

Fried

Smith

AM.

A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001; 23: 1–11.

120.

Goldschmidt

Day

Richardson

GA.

Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 2000; 22: 325–336.

121.

Day

Leech

Goldschmidt

The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicol Teratol 2011; 33: 129–136.

122.

Gunn

JKL

Rosales

Center

et al . Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 2016; 6: e009986.

123.

Brown

Mensah

Ah Kit

et al . Use of cannabis during pregnancy and birth outcomes in an Aboriginal birth cohort: a cross-sectional, population-based study. BMJ Open 2016; 6: e010286.

124.

Hayatbakhsh

Flenady

Gibbons

et al . Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 2012; 71: 215–219.

125.

Saurel-Cubizolles

M-J

Prunet

Blondel

Cannabis use during pregnancy in France in 2010. BJOG 2010; 121: 971–977.

126.

Varner

Silver

Rowland Hogue

et al . Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol 2014; 123: 113–125.

127.

Westfall

Janssen

Lucas

et al . Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’. Complement Ther Clin Pract 2006; 12: 27–33.

128.

American College of Obstetricians and Gynecologists and Committee on Obstetric Practice. Committee Opinion No. 637: marijuana use during pregnancy and lactation. Obstet Gynecol 2015; 126: 234–238.

129.

Patrick

Schumacher

Benneyworth

et al . Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307: 1934–1940.

130.

Patrick

Davis

Lehman

et al . Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009-2012. J Perinatol 2015; 35: 650–655.

131.

Källén

Reis

Ongoing pharmacological management of chronic pain in pregnancy. Drugs 2016; 76: 915–924.

132.

Cohen

Morley

Coombs

RC.

Maternal use of methadone and risk of sudden neonatal death. Acta Paediatr 2015; 104: 883–887.

133.

Burns

Conroy

Mattick

RP.

Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev 2010; 29: 551–556.

134.

Baldacchino

Arbuckle

Petrie

et al . Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 104.

135.

Maeda

Bateman

Clancy

et al . Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014; 121: 1158–1165.

136.

Whiteman

Salemi

Mogos

et al . Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014; 2: 906723–906728.

137.

Patrick

Dudley

Martin

et al . Prescription opioid epidemic and infant outcomes. Pediatrics 2015; 135: 842–850.

138.

Nezvalová-Henriksen

Spigset

Nordeng

Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol 2011; 67: 1253–1261.

139.

Desai

Huybrechts

Hernandez-Diaz

et al.

Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ 2015; 350: h2102.

140.

Kocherlakota

Neonatal abstinence syndrome. Pediatrics 2014; 134: e547–e561.

141.

Jones

Heil

Tuten

et al . Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend 2013; 131: 271–277.

142.

Choo

Huestis

Schroeder

et al . Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253–260.

143.

Kuczkowski

KM.

The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol 2007; 19: 578–585.

144.

Cain

Bornick

Whiteman

The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy. Clin Obstet Gynecol 2013; 56: 124–132.

145.

Buehler

Conover

Andres

RL.

Teratogenic potential of cocaine. Semin Perinatol 1996; 20: 93–98.

146.

Elliott

Loomis

Lottritz

et al . Case-control study of a gastroschisis cluster in Nevada. Arch Pediatr Adolesc Med 2009; 163: 1000–1006.

147.

Chasnoff

Burns

WJ.

Cocaine use in pregnancy: perinatal morbidity and mortality. Neurotoxicol Teratol 1987; 9: 291–293.

148.

Draper

Rankin

Tonks

et al . Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol 2008; 167: 485–491.

149.

Hannig

Phillips

JA.

Maternal cocaine abuse and fetal anomalies: evidence for teratogenic effects of cocaine. South Med J 1991; 84: 498–499.

150.

Bingol

Fuchs

Diaz

et al . Teratogenicity of cocaine in humans. J Pediatr 1987; 110: 93–96.

151.

Richardson

Goldschmidt

Larkby

et al . Effects of prenatal cocaine exposure on child behavior and growth at 10 years of age. Neurotoxicol Teratol 2013; 40: 1–8.

152.

Cressman

Natekar

Kim

et al . Cocaine abuse during pregnancy. J Obstet Gynaecol Can 2014; 36: 628–631.

153.

Lewis

Minnes

Short

et al . Language outcomes at 12 years for children exposed prenatally to cocaine. J Speech Lang Hear Res 2013; 56: 1662–1676.

154.

Dinsmoor

Irons

Christmas

JT.

Preterm rupture of the membranes associated with recent cocaine use. Am J Obstet Gynecol 1994; 171: 305–308; discussion 308–309.

155.

Mbah

Alio

Fombo

et al . Association between cocaine abuse in pregnancy and placenta-associated syndromes using propensity score matching approach. Early Hum Dev 2012; 88: 333–337.

156.

Gouin

Murphy

Shah

et al . Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol 2011; 204: 340.e1–341.e12.

157.

Martinez

Larrabee

Monga

Cocaine is associated with intrauterine fetal death in women with suspected preterm labor. Am J Perinatol 1996; 13: 163–166.

158.

Shah

Diaz

Arria

et al . Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol 2012; 29: 391–400.

159.

Gorman

Orme

Nguyen

et al . Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol 2014; 211: 429.e1–429.e7.

160.

Good

Solt

Acuna

et al . Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol 2010; 116: 330–334.

161.

Oei

Kingsbury

Dhawan

et al . Amphetamines, the pregnant woman and her children: a review. J Perinatol 2012; 32: 737–747.

162.

Lagasse

Derauf

Smith

et al . Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics 2012; 129: 681–688.

163.

Diaz

Smith

Lagasse

et al . Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. J Pediatr 2014; 164: 1333–1338.

164.

Chang

Cloak

Jiang

et al . Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage 2009; 48: 391–397.

165.

Chang

Smith

LoPresti

et al . Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res 2004; 132: 95–106.

166.

Wright

Schuetter

Tellei

et al . Methamphetamines and pregnancy outcomes. J Addict Med 2015; 9: 111–117.

167.

Ladhani

NNN

Shah

Murphy

et al . Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205: 219.e1–219.e7.

168.

Brecht

M-L

Herbeck

DM.

Pregnancy and fetal loss reported by methamphetamine-using women. Subst Abuse 2014; 8: 25–33.

169.

Wright

Terplan

Ondersma

et al . The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol 2014; 215: 539–547.

170.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obst Gynecol 2008; 112: 1449–1460.

171.

Wong

Ordean

Kahan

et al . Substance use in pregnancy. J Obstet Gynaecol Can 2011; 33: 367–384.

172.

McLafferty

Becker

Dresner

et al . Guidelines for the management of pregnant women with substance use disorders. Psychosomatics 2016; 57: 115–130.

173.

Kerker

Horwitz

Leventhal

JM.

Patients’ characteristics and providers’ attitudes: predictors of screening pregnant women for illicit substance use. Child Abuse Negl 2004; 28: 209–223.

174.

Petersen Williams

Petersen

Sorsdahl

et al . Screening and brief interventions for alcohol and other drug use among pregnant women attending midwife obstetric units in Cape Town, South Africa: a qualitative study of the views of health care professionals. J Midwifery Womens Health 2015; 60: 401–409.

175.

Anderson

Dang

Floyd

et al . Knowledge, opinions, and practice patterns of obstetrician-gynecologists regarding their patients’ use of alcohol. J Addict Med 2010; 4: 114–121.

176.

Benoit

Stengel

Marcellus

et al . Providers’ constructions of pregnant and early parenting women who use substances. Sociol Health Illn 2014; 36: 252–263.

177.

Hotham

Ali

White

et al . Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in pregnancy. Addict Disord Their Treat 2013; 12: 123–135.

178.

Sokol

Martier

Ager

JW.

The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol 1989; 160: 863–870.

179.

Russell

Martier

Sokol

et al . Screening for pregnancy risk-drinking. Alcohol Clin Exp Res 1994; 18: 1156–1161.

180.

Yonkers

Gotman

Kershaw

et al . Screening for prenatal substance use: development of the substance use risk profile-pregnancy scale. Obstet Gynecol 2010; 116: 827–833.

181.

Chasnoff

Wells

McGourty

et al . Validation of the 4P’s Plus screen for substance use in pregnancy validation of the 4P’s Plus. J Perinatol 2007; 27: 744–748.

182.

Mayfield

Mcleod

Hall

The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. Epub ahead of print 12 February 2015. DOI: 10.1176/ajp.131.10.1121.

183.

Selzer

Vinokur

van Rooijen

A self-administered Short Michigan Alcoholism Screening Test (SMAST). J Stud Alcohol 1975; 36: 117–126.

184.

Bottoms

Martier

Sokol

RJ.

Refinements in screening for risk drinking in reproductive-aged women: the ‘NET’ results. Alcohol Clin Exp Res 1989; 13: 339.

185.

Saunders

Aasland

Babor

et al . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993; 88: 791–804.

186.

Bush

Kivlahan

McDonell

MB.

The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789–1795.

187.

Burns

Gray

Smith

LA.

Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction 2010; 105: 601–614.

188.

Chang

Screening for alcohol and drug use during pregnancy. Obstet Gynecol Clin North Am 2014; 41: 205–212.

189.

Terplan

McNamara

Chisolm

MS.

Pregnant and non-pregnant women with substance use disorders: the gap between treatment need and receipt. J Addict Dis 2012; 31: 342–349.

190.

Haug

Duffy

McCaul

ME.

Substance abuse treatment services for pregnant women: psychosocial and behavioral approaches. Obstet Gynecol Clin North Am 2014; 41: 267–296.

191.

Project CHOICES Intervention Research Group. Reducing the risk of alcohol-exposed pregnancies: a study of a motivational intervention in community settings. Pediatrics 2003; 111: 1131–1135.

192.

Whiteside-Mansell

Crone

Conners

NA.

The development and evaluation of an alcohol and drug prevention and treatment program for women and children. The AR-CARES program. J Subst Abuse Treat 1999; 16: 265–275.

193.

Armstrong

Gonzales Osejo

Lieberman

et al . Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol 2003; 23: 3–9.

194.

Forray

Substance use during pregnancy. F1000Res 2016; 5: 887.

195.

Terplan

Ramanadhan

Locke

et al . Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev 2015; 4: CD006037.

196.

Lui

Terplan

Smith

EJ.

Psychosocial interventions for women enrolled in alcohol treatment during pregnancy. Cochrane Database Syst Rev 2008; 3: CD006753.

197.

Stade

Bailey

Dzendoletas

et al . Psychological and/or educational interventions for reducing alcohol consumption in pregnant women and women planning pregnancy. Cochrane Database Syst Rev 2009; 2: CD004228.

198.

Gilinsky

Swanson

Power

Interventions delivered during antenatal care to reduce alcohol consumption during pregnancy: a systematic review. Addict Res Theory 2010; 19: 235–250.

199.

Rendall-Mkosi

Morojele

London

et al . A randomized controlled trial of motivational interviewing to prevent risk for an alcohol-exposed pregnancy in the Western Cape, South Africa. Addiction 2013; 108: 725–732.

200.

Chersich

Urban

Olivier

et al . Universal prevention is associated with lower prevalence of fetal alcohol spectrum disorders in Northern Cape, South Africa: a multicentre before-after study. Alcohol Alcohol 2012; 47: 67–74.

201.

de Vries

Joubert

Cloete

et al . Indicated prevention of fetal alcohol spectrum disorders in South Africa: effectiveness of case management. Int J Environ Res Public Health 2016; 13: 76.

202.

Burns

Coleman-Cowger

Breen

Managing maternal substance use in the perinatal period: current concerns and treatment approaches in the United States and Australia. Subst Abuse 2016; 10: 55–61.

203.

DeVido

Bogunovic

Weiss

RD.

Alcohol use disorders in pregnancy. Harv Rev Psychiatry 2015; 23: 112–121.

204.

Lingford-Hughes

Welch

Peters

et al . BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol (Oxford, England) 2012; 26: 899–952.

205.

Nora

Blu

Limb-reduction anomalies in infants born to disulfiram-treated alcoholic mothers. Lancet 1977; 2: 664.

206.

Helmbrecht

Hoskins

IA.

First trimester disulfiram exposure: report of two cases. Am J Perinatol 1993; 10: 5–7.

207.

Rolland

Paille

Gillet

et al . Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther 2016; 22: 25–37.

208.

Kelty

Hulse

A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs 2017; 77: 1211–1219.

209.

Hulse

O'neil

Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002; 42: 569–573.

210.

Hulse

O'neil

Arnold-Reed

DE.

Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 2004; 85: 170–171.

211.

Rösner

Hackl-Herrwerth

Leucht

et al . Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; 295: CD004332.

212.

Oncken

Kranzler

HR.

What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

Nicotine Tob Res 2009; 11: 1265–1273.

213.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 721. Smoking cessation during pregnancy. Obstet Gynecol 2017; 130: e200–204.

214.

Richardson

Stephens

Yates

et al . Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol 2017; 67: 26–34.

215.

Chun-Fai-Chan

Koren

Fayez

et al . Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192: 932–936.

216.

Cole

Modell

Haight

et al . Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474–484.

217.

Alwan

Reefhuis

Botto

et al . Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010; 203: 52.e1–52.e6.

218.

Chisolm

Payne

JL.

Management of psychotropic drugs during pregnancy. BMJ 2016; 532: h5918.

219.

Nanovskaya

Oncken

Fokina

et al . Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. Am J Obstet Gynecol 2017; 216: 420.e1–420.e9.

220.

Jones

O'grady

Malfi

et al . Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372–386.

221.

Wilder

Winhusen

Pharmacological management of opioid use disorder in pregnant women. CNS Drugs 2015; 29: 625–636.

222.

Kandall

Doberczak

Jantunen

et al . The methadone-maintained pregnancy. Clin Perinatol 1999; 26: 173–183.

223.

ACOG Committee on Health Care for Underserved Women and American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119: 1070–1076.

224.

Jones

Kaltenbach

Heil

et al . Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320–2331.

225.

Mattick

Breen

Kimber

et al . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 66: CD002207.

226.

Jansson

Velez

McConnell

et al . Maternal buprenorphine treatment and fetal neurobehavioral development. Am J Obstet Gynecol 2017; 216: 529.e1–529.e8.

227.

Wouldes

The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004; 26: 23–34.

228.

Minozzi

Amato

Bellisario

et al . Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; 94: CD006318.

229.

Tran

Griffin

Stone

et al . Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy 2017; 37: 824–839.